GWS
RIGL icon

Glassman Wealth Services’s Rigel Pharmaceuticals RIGL Stock Holding History

Glassman Wealth Services’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3
Closed – – 1863
2021
Q3 		$0 Hold
3
– – ﹤0.01% 1765
2021
Q2 		$0 Hold
3
– – ﹤0.01% 1608
2021
Q1 		$0 Buy
+3
New +$119 ﹤0.01% 1595

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Glassman Wealth Services's RIGL Position: Q4 2021 in Review

Glassman Wealth Services sold out of Rigel Pharmaceuticals (RIGL) in Q4 2021, closing a stake of 3 shares.

Glassman Wealth Services first reported a position in RIGL in Q1 2021 and held it in 3 quarters. The position peaked at $0 in Q3 2021. 162 funds tracked by Wall St. Rank hold RIGL as of Q4 2021.

  • Glassman Wealth Services reported no remaining Rigel Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Glassman Wealth Services sold 3 Rigel Pharmaceuticals shares in Q4 2021.
  • Glassman Wealth Services first reported a position in Rigel Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Glassman Wealth Services's Rigel Pharmaceuticals position peaked at $0 in Q3 2021.
  • 162 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2021.

Based on Glassman Wealth Services's 13F filing for Q4 2021, filed 14 Feb 2022.